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A NOVEL KUNITZ-TYPE SERINE PROTEASE INHIBITOR FROM THE HOOKWORM, 
ANCYLOSTOMA CEYLANICUM. Aaron M. Milstone, Lisa M. Harrison, and Michael Cappello. 
Section of Infectious Diseases, Departments of Pediatrics and Epidemiology & Public Health, Yale 
University, School of Medicine, New Haven, CT. 
Hookworms, blood feeding intestinal nematodes, infect more than one billion people in the 
developing world. Because little is known about the role of protease inhibitors in the pathogenesis of 
human hookworm disease, we have recently devised a molecular strategy aimed at isolating cDNAs that 
encode related serine protease inhibitors from adult Ancylostoma ceylanicum, a human hookworm 
parasite. Using a combination of RT-PCR and 3' RACE, we have recently cloned the first Kunitz-type 
serine protease inhibitor from A. ceylanicum. The tr anslated sequence of the cDNA encoding the mature 
Ancylostoma ceylanicum Kunitz-type Inhibitor 1 (AceKI-1) predicts a 68 amino acid protein with a MW 
of 7889 Da and a presumed methionine residue at its putative P1 inhibitory reactive site. The AceKI-1 
cDNA was cloned into the pET28a expression vector, and recombinant protein (rAceKI-1) was purified 
from induced lysates of E. Coli transformed with the rAceKI-1/pET 28a plasmid. Using single stage 
chromogenic assays, we have determined that rAceKI-1 is a potent inhibitor of the serine proteases 
chymotrypsin (K* = 485 pM), porcine pancreatic elastase (K, = 277 pM), and human neutrophil elastase 
(K* = 1.06 nM). The inhibitor shows weaker inhibitory activity against trypsin (K, = 21 nM) and no 
activity against coagulation proteases factor Xa and thrombin. Additional studies have revealed that 
soluble protein extracts from the hookworms A. ceylanicum, A. caninum and Necator americanus contain 
identical inhibitory activities, suggesting that chymotrypsin/elastase/trypsin inhibition is a broadly 
conserved evolutionary strategy of adult hookworms. To confirm this biological activity in vivo, we have 
purified the native inhibitor from soluble extracts of A. ceylanicum, using size exclusion and rpHPLC 
chromatographies. Work is currently underway to further characterize the unique mechanism of protease 
inhibition by AceKI-1, as well as to determine its biologic role in parasite survival and the pathogenesis 
of hookworm anemia. 
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Hookworm infection affects up to one billion people in the developing world and 
is a major cause of gastrointestinal blood loss and iron deficiency anemia. Hookworm 
disease has plagued mankind for thousands of years. Physicians in ancient China were 
quoted as describing those with “able to eat but too lazy to work yellow disease” (1). In 
1880, an epidemic struck Italian laborers building a railway tunnel in the Swiss Alps, 
afflicting them with what was tenned miner’s anemia. In an attempt to rid the 
Southeastern United States of rampant infection, the Rockefeller Sanitary Commission 
for the Eradication of Hookworm Disease was launched in 1909. Hookworms quickly 
gained respect not just as the “germ of laziness”, but also as a major cause of clinical 
disease. John D. Rockefeller hoped his Commission could help “relieve human 
suffering”(2). Through increased public health awareness, the Commission spawned 
research to study hookworm biology and the pathogenesis of hookworm disease (3). 
Almost a century later, hookworm infection continues to plague approximately one fifth 
of the world’s population. We now know, however, that the presence of hookworm in 
their human host is not the problem; it is disease these hookworms cause that we hope to 
eliminate. 
In human populations the prevalence of hookworm infection depends upon the 
presence of an environment that is suitable for development and survival of hookworm 
eggs and larvae, an environment where soil is contaminated with feces, and where 
humans are in contact with the contaminated soil (4). Consistently, hookworm infection 
is predominant in parts of the rural tropics where poor sanitary conditions and the use of 
human feces as fertilizer provide a favorable climate for parasite transmission. 

? 
Hookworms infect people of all ages with peak prevalence in late adolescence. An 
increased rate of infection in older children and adults may result from a greater 
likelihood of this group contacting contaminated soil. Prevalence of hookworm has been 
reported as high as 87% in some areas of Kenya (5), but commonly 30% of people in a 
population will have intense infections, harboring 70% of the total worm burden (6). 
Ancylostoma duodenale is the most prevalent human hookworm pathogen and is 
predominantly found in India, China, and Mediterranean areas of Africa and Europe, and 
has been described in Latin America as well (7). A. ceylanicum is an infrequent parasite 
of humans in India and Southeast Asia (8,9), but its ability to also affect other animals 
including dogs, cats, and hamsters makes it one of the easier species to study using 
animal models (10). Necator americanus, the New World hookworm, named because of 
its widespread distribution in the Caribbean and the Americas, is also found in the Pacific 
Islands, Sub-Saharan Africa, and Southeast Asia. 
Figure 1: Necator americanus (left) and Ancylostoma duodenale (right) 
Hookworms are nematodes of the family Ancylostomidae and are differentiated 
by their buccal teeth or cutting plates (see figure 1). Two important genera of 
hookworms, Ancylostoma and Necator, are responsible for most clinical disease in 
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humans. Species of Ancylostoma, including A. braziliense (cat hookworm) and A. 
caninum (dog hookworm) generally invade the human host percutaneously and cause 
cutaneous larva migrans. Ancylostoma duodenale, A. ceylanicum, and Necator 
americanus invade percutaneously, but they complete their lifecycle in the host, 
becoming adult blood feeding worms. Additionally, Ancylostoma can be transmitted by 
oral ingestion of contaminated food or soil (11). Vertical transmission of A. caninum has 
been demonstrated in the colostrum and milk of dogs, and although A. duodenale has not 
been isolated human milk, a high prevalence of infection in infants and young children 
has led to suggestions that it, too, can be transmitted vertically (12). 
Hookworms infect humans by a rather indirect route (see figure 2). Adult female 
worms in the host intestine produce thousands of eggs that are expelled in the host’s 
feces. These eggs are best suited for damp, sandy, and friable soil in a warm and shady 
climate, where they will hatch into microscopic larvae, feed on bacteria and organic 
debris, and undergo two developmental molts (13). Larvae can live for up to a month in 
the soil before entering a host to continue development. Third stage infective larvae will 
migrate up in the soil and can exhibit “questing behavior” as they climb up a blade a 
grass, stand upright, and sway, awaiting contact with a host. 
Hookworms contact human skin typically on the feet and legs, where they enter 
percutaneously by burrowing into the skin (14). In previously exposed individuals, an 
inflammatory response leads to the accumulation of white blood cells and an often 
intense itch. The hookworm larva penetrates the epidennis, the basement membrane, the 
lymphatics and venules in the skin, and is then carried in the circulation to the right side 
of the heart. After reaching the pulmonary capillaries, the larva penetrates the lung 

parenchyma and ascends to the trachea before being coughed up and swallowed by the 
host. In the small intestine the third stage infective larva undergoes two additional molts 
sexually differentiates into a blood feeding adult, and attaches to the intestinal mucosa. 
4 
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Figure 2: The lifecycle of A. duodenale. (13) 
The lifecycle begins with development of the egg in the soil (1 -4). Infective larvae (L3) usually 
penetrate the skin and follow the venous circulation to the lungs, eventually making their way to 
the intestine (5-9). Mature adults copulate and eggs are excreted in feces to renew the lifecycle in 
the soil (10,11). A. duodenale has been shown to establish infection following oral ingestion (5a). 




Within two months of arriving in the host as larvae, adult female worms lay eggs which 
are passed with feces into the soil to continue the transmission cycle. 
Dr. Gerhard Schad identified a divergence from this cycle when he demonstrated 
A. cluodenale larvae’s ability for arrested development in their host (15). The infective 
larvae can remain dormant for months in the host, often in skeletal muscle, before 
maturing to a patent adult. Dormancy may have a selective advantage for hookworms. If 
eggs are laid into soil that is dry and hot, then they will not survive. Arrested larvae have 
been shown to resume development with seasonal periodicity, which leads to speculation 
that larvae develop to peak ova-producing adults by onset of monsoon season, 
presumably to ensure for egg deposition into moist soil (16). 
The presence of a few hookworms in the human intestine is clinically benign, but 
in cases of heavy worm burden, the resulting hookworm disease, namely iron deficiency 
anemia, can be lethal (17). While in the small 
intestine, most often the jejunum (18), the 
hookworm attaches to the intestinal mucosa by 
its specialized teeth (A. duodenale) or cutting 
plates (N. americanus). The parasite’s muscular 
pharynx creates negative pressure sucking in a 
plug of mucosal membrane and underlying 
tissue (see photo to right). Lysis of mucosal 
cells and localized tissue damage leads to 
rupture of capillaries in the lamina propria and 
hemorrhage (19). Primary blood loss occurs as 

blood passes through the intestine of the worm, and secondarily from leakage around the 
worm’s attachment site (20). Bleeding also occurs at previous attachment locations as 
worms move to new sites and from occasional extensive intestinal hemorrhage (21). It 
has been estimated that each adult A. duodenale can cause 0.2 - 0.4 cc of blood loss per 
day (22) while N. americanus are less aggressive feeders and result in only ten percent of 
the blood loss of A. duodenale. As mentioned earlier, many infected people harbor few 
worms, but those with high intensity infection are at risk for clinically significant blood 
loss. In such cases, studies with A. duodenale and N. americanus infection have shown 
daily losses of 4.8 mg iron (23) and 2 mg iron (24), respectively, up to five times the 
daily median requirement of iron for a healthy school-age child. Plasma protein is also 
lost in the blood and hypoproteinemia can be seen in heavily infected individuals. 
Many studies have tried to correlate intestinal worm load, estimated by fecal egg 
count, and the resulting anemia, measured by hemoglobin concentration (25). The 
hemoglobin level, however, only declines when total body iron stores have been 
depleted. The development of iron deficiency anemia, therefore, is dependent not only 
upon the intensity and chronicity of infection, but also upon the host’s total body stores 
and dietary iron intake. Children and women usually have the lowest iron stores and are 
therefore most susceptible to developing iron deficiency anemia, especially in the context 
of insufficient iron intake and malnutrition. Some studies have estimated that 20-80% of 
iron and other blood constituents can be reabsorbed further along in the intestine; 
however, common co-infections with Ascaris lumbricoides and Trichuris trichiura can 
impair the absorptive surface of the gut (26). Ultimately, though, if the infection is 
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treated and there is sufficient iron intake, then the hemoglobin levels will rise and the 
anemia will resolve (27). 
The most significant clinical complication from hookworm infection is the iron 
deficiency anemia that results from chronic gastrointestinal blood loss. Growth 
retardation is a sequela of iron deficiency that can be reversed by iron supplementation 
(28). The effects of iron deficiency on mental performance, however, have been long 
debated. Observations in the Southeastern United States that had termed hookworms the 
“germ of laziness” also noted improvements in mental alertness that occurred following 
treatment of heavily infected children (2). Studies have correlated iron deficiency anemia 
in children with lower test scores on intelligence tests and decreased scholastic 
performance. Although the mechanism for this is unknown, it has been shown that as 
iron stores are depleted in the host, there is a decrease in iron containing enzymes such as 
monoamine oxidase, an enzyme involved in the production of the neurotransmitters 
serotonin, dopamine and norepinephrine (29). Overall, Pollitf s in depth review of the 
often contradictory literature concluded that hookworm infection can cause cognitive 
impairment (5). 
The ideal approach to prevention of hookworm infection relies on improvement in 
the quality of life with better sanitation and water supplies as demonstrated in the 
southeastern United States. Better sanitary systems, however, are not imminent in the 
developing world. Popular literature has argued that wearing shoes would help reduce 
transmission of hookworm, but arguments to the contrary point out the incidence of 
reinfection from activated dormant larvae (11). Current strategies targeting hookworm 
infection involve treatment with anthelmintic agents. A single oral dose of albendazole 

or mebendazole can remove adult hookworms from the small intestine. In endemic areas, 
however, reinfection is common within 4-12 months of treatment. Additionally, 
anthelminthics do not target dormant larvae, and in order to prevent anemia, multiple 
courses of treatment are required (30). Although effective and inexpensive (by 
developed nation standards), these drugs are contraindicated in patients with blood 
dyscrasias, leukopenia, and liver disease, and concerns remain about embryo toxicity and 
teratogenicity (7,24). Additionally, as has been seen with many classes of antibiotics, the 
development of drug resistance is possible with continued widespread usage of 
anthelminthics (31). The interventions present to target global hookworm disease, are 
therefore either improbable or have potential risks. Currently no human hookworm 
vaccine exists mainly due to a lack of understanding of hookworm biology. Further 
discovery of the requirements for parasite survival and the pathogenesis of hookworm 
anemia will hopefully lead to the development of a novel treatment strategy to eliminate 
hookworm disease. 
Hookwonns secrete various molecules that potentially aid in parasite survival and 
the pathogenesis of hookworm anemia. Targeting these virulence factors may serve as a 
new approach to alleviating hookworm disease (32). As a result, killing the worm may 
not be necessary to prevent disease; neutralizing the virulence factors that enable it to 
blood feed and evade the host immune response may be sufficient. These substances 
include anticoagulants, antiplatelet agents, protease inhibitors, proteases, hyaluronidases, 
and anti-inflammatory agents. These molecules are presumed to enable hookwonns to 
penetrate the skin, travel passively through the blood stream to lodge in the capillaries of 
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the lungs, invade the intestinal mucosa, and cause sufficient blood loss to induce iron 
deficiency anemia, all occurring in the absence of an effective host immune response. 
Hookworms have evolved the ability to secrete molecules that facilitate tissue 
invasion. The third stage (L3) infective larva of Ancylostoma caninum secretes a 
hyaluronidase speculated to break the hyaluronan bridges connecting epidermal 
keratmocytes and aid in percutaneous invasion (16). Secreted metalloproteases may also 
play a role in breaking down connective tissue banners allowing the spread of other 
secreted proteins (33). A proteolytic enzyme from adult A. caninum is produced 
presumably for degrading and lysing the engulfed bolus of host intestinal mucosa (34). 
Likewise, Necator americanus contains a variety of proteolytic activities in vitro, thought 
to be responsible for digesting host tissues (35). 
Hookwonns produce proteins, proteases, and protease inhibitors that may aid the 
parasite in surviving the host environment and evading the immune response. A serine 
protease inhibitor has been cloned from Ancylostoma caninum, named Catrin, with 
specific inhibitory activity against trypsin (36). Inhibiting trypsin may enable the worm 
to survive the hydrolytic environment of the gastrointestinal tract. A neutrophil 
inhibitory factor (NIF) has been cloned from adult Ancylostoma caninum excretory and 
secretory products (ES products), which binds to a GDI 1/CD18 receptor of neutrophils 
and inhibits phagocytosis and the release of oxidants (37). A 42 kD protein, named 
Ancylostoma Secreted Protein, has also been cloned from activated infective larval stage 
Ancylostoma caninum ES products (38). This secreted protein has unknown function but 
is similar in sequence to NIF. Proteases from A. caninum also demonstrate homology to 
cysteine proteases from H. contortus that cleave immunoglobulins (39). N. americanus 
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secretes a superoxide dismutase and a glutathione-S-transferase, antioxidants that can 
neutralize free radicals (40). All these substances are thought to help hookworms evade 
destruction by interfering with the host environment and immune response. 
Hookworms have also evolved the ability to enhance blood feeding by secreting 
proteins and protease inhibitors that inhibit coagulation and platelet aggregation. This 
phenomenon was described as early as 1910 by Loeb and Fleisher who described a 
substance in hookworm homogenates that targeted and inactivated a host protein, thereby 
inhibiting blood coagulation and facilitating blood loss (41). More recently, distinct 
serine protease inhibitors from Ancylostoma caninum have been cloned and characterized 
including AcAPc2, which has inhibitory activity against the complex of coagulation 
factor Vila and tissue factor (42), and AcAP5, which has activity against coagulation 
factor Xa (43, 44). A. caninum has also been shown to secrete a potent inhibitor of 
platelet function which blocks platelet binding to immobilized fibrinogen and collagen by 
the glycoproteins Ilb/IIIa and Ia/IIb (45). One can speculate that Ancylostoma has 
evolved this complex strategy to block blood coagulation and platelet interaction to 
facilitate and enhance blood feeding. 
These hookworm proteins, proteases, and protease inhibitors are believed to be 
essential components in the pathogenesis of human hookworm disease. Michael 
Cappello’s laboratory is working to identify novel protease inhibitors from adult 
hookworms, which ultimately may contribute to parasite survival within its mammalian 
host. Some inhibitors may lead to increased blood loss and the development of anemia 
and others may have different functions. More specifically. Dr. Cappello is targeting 
serine protease inhibitors from Ancylostoma ceylanicum because this human parasite also 

infects other animals including dogs, cats, and hamsters, and therefore can be studied as a 
model for human disease (46). 
As mentioned above, a number of serine protease inhibitors have been cloned 
from adult hookworms. Both AcAP5 and AcAPc2 are members of the Ascaris family of 
protease inhibitors, first identified in the non-blood feeding intestinal nematode Ascciris 
suuni. Catrin, also cloned from A. caninum, is a trypsin inhibitor that belongs to the 
Kunitz family. The serine protease inhibitors are divided into families based upon the 
configuration of disulfide bridges and the sequential location of their reactive site (47) 
(see discussion). The pattern of intrachain disulfide bridges is conserved within families, 
helping to categorize newly identified protease inhibitors. Some of the families include 
the Kunitz (Bovine Pancreatic Trypsin Inhibitor) Family, the Kazal (Pancreatic Secretory 
Trypsin Inhibitor) Family, the Bowman-Birk Inhibitor Family, the Serpins, and the 
Ascaris Trypsin Inhibitor Family. It has been hypothesized that the AcAP inhibitors 
facilitate hookworm blood feeding, while Catrin may protect the adult worm from 
trypsin-mediated proteolysis within the mammalian intestine. Intuitively, one could 
assume that these inhibitory activities represent a conserved evolutionary strategy for 
survival in all species of hookworm. In such a case, these virulence factors would serve 
as suitable targets for either drug or vaccine development. Therefore, Dr. Cappello 
devised a molecular strategy to identify novel serine protease inhibitors from adult 
Ancylostoma ceylanicum. More specifically, this project started with the goal of 
identifying a factor Xa inhibitor from adult A. ceylanicum, similar to the Ascaris-type 
inhibitor of coagulation factor Xa he had previously isolated from the dog hookworm 
Ancylostoma caninum (42). 
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Why are we interested in identifying and cloning novel protease inhibitors? We 
hypothesize that these inhibitors serve as hookworm virulence factors and play a biologic 
role in parasite survival and the pathogenesis of hookworm anemia. Because of their 
likely role in parasite survival, interfering with protein virulence factors using 
chemotherapeutics or immunotherapy can be a new therapeutic strategy at alleviating 
hookworm disease . 
STATEMENT OF PURPOSE: 
Protease inhibitors have been identified in multiple species of hookworms. The purpose 
of this research project was to identify novel serine protease inhibitors from Ancylostoma 
ceylanicum that may act as virulence factors and play a biologic role in parasite survival 
and the pathogenesis of hookworm anemia. We propose to use gene sequences from 
previously identified protease inhibitors to facilitate our cloning efforts. 
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Materials and Methods: 
Hookworms: The life cycle of the hookworm Ancylostoma ceylanicum was maintained 
in our laboratory by Dr. Richard Bungiro and Esfir Kruglov, using a previously described 
hamster model (48). Infective third stage (L3) A. ceylanicum larvae were provided 
initially by Drs. John Hawdon and Peter Hotez at Yale University School of Medicine. 
Three week old Syrian hamsters (LVG strain) were infected orally by gavage with 100- 
150 L3 per animal. Approximately 21 days post infection, the hamsters were euthanized 
and the live adult hookworms harvested manually from the intestinal mucosa. Adult 
Ancylostoma caninum were obtained from the intestines of laboratory infected dogs using 
a similar protocol (49). Adult Necator americanus hookworms were harvested from 
hamsters in the laboratory of Dr. David Pritchard of the Department of Life Sciences at 
The University of Nottingham (Nottingham, England). 
Hookworm Extracts and Excretory and Secretory Products : Extracts of adult 
hookworms were prepared by manually homogenizing the adult worms in 50 mM Tris- 
HC1 pH 7.5 using a glass homogenizer. Soluble protein extracts, which represented the 
starting material for the purification and characterization of Ancylostoma ceylanicum 
Kunitz-type Inhibitor-1 (AceKI-1), were obtained by centrifugation at 10,000 x g. Protein 
concentrations of each lot of hookworm extracts were determined using the BCA reagent 
from Pierce (Rockford, IL). Extracts of infective larval stage (L3) hookworms were 
prepared similarly to the adult extracts. Adult hookworm excretory and secretory 
products (ES products) were prepared by incubating live, freshly harvested adult worms 
in RPMI media with or without host serum (5%) overnight at 37° C in 5% C03. The 
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worms were removed and the secretory products clarified by centrifugation at 10,000 x g 
prior to use. 
RNA Extraction: Fifty adult Ancylostoma ceylanicum were resuspended in 1.0 ml of 
Trizol (Gibco/BRL; Gaithersberg, MD); total RNA isolation was carried out according to 
the manufacturer’s protocol. In brief, 50 worms were homogenized in 1.0 ml Trizol and 
incubated at 25°C for 10 min to allow for complete dissociation of nucleoprotein 
complexes. Following 5 min incubation with 200 pi of chloroform, the sample was 
centrifuged and the aqueous phase removed. Total RNA was precipitated by incubating 
the aqueous phase with 500 pi isopropyl alcohol at 25°C, followed by centrifugation. 
The RNA pellet was washed with 75% and 100% ethanol, air dried for 10 min, and 
resuspended in 40 pi diethyl pyrocarbonate (DEPC)-treated water. 
Reverse transcription-polymerase chain reaction (RT-PCR) : RT-PCR of total adult 
A. ceylanicum RNA was utilized to obtain the A. ceylanicum complementary DNA (50). 
All primers were synthesized by the William Keck Foundation Biotechnology Resource 
Laboratory at Yale University School of Medicine (see figure 3). 
First strand cDNA was synthesized by incubating approximately 1 pg RNA, 10 mM 
DTT and 100 ng 3’CKDGFYRD in Superscript 5X first strand reaction buffer (50 mM 
Tris-HCl, 75 mM KC1, 3 mM MgCC, pH 8.3) (Gibco/BRL). The solution was heated for 
90 sec at 90°C and cooled on ice. Each of four deoxynucleotides (1 mM; dATP, dCTP, 
dGTP,dTTP; New England Biolabs, Beverly, MA) was added along with 40 U RNasin 
(Promega; Madison, WI) and 200 U reverse transcriptase enzyme (Superscript II; Gibco- 








(2) 3’ CKDGFYRD 
(3) 5’ KUNITZ1A 







5' GTCTCTGTAGAATCCGTCKTYGCA 3' 








Figure 3 : Primers for cloning rAceKI-1 
Initial cDNA sequence was obtained through RT-PCR using a sense strand PCR primer (1) which 
corresponds to the nematode spliced leader sequence present in the 5’ region of many nematodes 
mRNAs (51-53). A degenerate antisense strand primer (2) is homologous to a conserved region 
(CKDGFYRD) observed near the carboxy-terminus of Ascctris-type inhibitors (42). To clone the 
3’ end, RT-PCR with an antisense oligo (dT) primer (4) was used along with an internal primer 
(3) designed from initial sequence. 
The entire first strand cDNA mixture was combined with : PCR primers 5’SLXHO and 
3’CKDGFYRD (100 ng each), PCR buffer (60 mM Tris-HCl, 15 mM NH4S04, 1.5 mM 
MgCfi, pH 10.0), and 1 mM deoxynucleotides. The reaction mixture was brought to a 49 
ml total volume with DEPC water. Amplitaq taq polymerase enzyme (5 U; Perkin-Elmer, 
Foster City, CA) was then added and samples were placed in a thermal cycler (PCR 
Sprint, Hybaid; Middlesex, UK) for 40 cycles (94°C for 15 sec denaturation, 55°C for 5 
sec annealing, and 72°C for 30 sec extension). The PCR product reaction mixture was 
subjected to 1% agarose gel electropheresis and visualized by ethidium bromide staining. 
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3’ RACE (Rapid Amplification of cDNA Ends) : RT-PCR was performed, as above, 
using 1 pg RNA and an antisense oligo (dT) primer, 3’ TTTT. The first strand cDNA 
mixture was added to PCR reagents, including primers 3’ TTTT and 5’KUNITZ1A, an 
internal primer designed to initial sequence obtained (see figure 3). The mixture was 
placed in the thermal cycler for 40 cycles, as above using same concentration reagents 
and cycling conditions. 
DNA Sequencing : The resulting PCR product was ligated into the pCR2.1 (Invitrogen; 
Carlsbad, CA) TA cloning vector by incubating ~10 ng PCR product, 50 ng pCR 2.1 
vector, T4 DNA ligase, and ligation buffer overnight at 14°C. One Shot E. coli INVaF’ 
(Invitrogen) were transformed with the ligation product as per manufacturer’s protocol. 
In brief, after mixing the E. coli with 0.5 M B-mercaptoethanol, 10% of the ligation 
product was added and incubated on ice for 30 min, followed by a 30 sec heat shock at 
42°C and then 2 min on ice. SOC medium was added to the transformed bacteria and 
incubated for 1 hr at 37°C 250 RPM. Samples were plated on LB agar plates with 30 
pg/mL kanamycin (G1BCO/BRL) and grown overnight at 37°C. Colonies which grew on 
the selective media were screened for the appropriate sized insert by direct colony PCR 
using vector specific primers (T7 Promoter, M13 Reverse), and by restriction enzyme 
digest (EcoRI; New England Biolabs) of isolated plasmid DNA. Miniprep plasmid DNA 
(Spin Miniprep Kit, QIAGEN; Valencia, CA) from positive colonies was sent to the 
William Keck Foundation Biotechnology Resource Laboratory at Yale University School 
of Medicine for nucleotide sequencing. 
Sequence Analysis : Sequences were analyzed for homology to other known sequences 
using the BLAST algorithm through the National Center for Biotechnology Information 

17 
(http://www.ncbi.nlm.nih.gov/BLAST/) (54). The full length translated amino acid 
sequence was analyzed using SignalP Program used for determination of the signal 
sequence cleavage site (http://www.cbs.dtu.dk/services/SignalP/index.html) (55,56). 
Expression of Recombinant AceKI-1 (rAceKI-1): In order to clone the entire AceKI-1 
cDNA corresponding to the predicted mature protein into a prokaryotic expression 
vector, RT-PCR was perfonned again, as above, using 3’ ACEKIXHO and 5’ 
ACEKIBAM primers. The 5’ primer was designed based on the mature protein’s 
predicted NPE-terminal amino acid residues. Purified rAceKl-1 cDNA (PCR Purification 
Kit; QIAGEN, Valencia, CA) was digested with BamWX and Xho\ (New England 
Biolabs) and directionally cloned into the pET28a expression plasmid vector (Novagen; 
Madison, WI). The pET28a plasmid encodes a polyhistidine fusion protein tag at the 
amino terminus (AlaSerMetThrGlyGlyGlnGlnMetGlyArg) and a T7 Tag at the carboxy 
end. The ligated pET28a plasmid containing the AceKI-1 cDNA was transformed into 
ultracompetent E. coli strain BL21 (DE3) cells (Stratagene; La Jolla, CA) and samples 
were plated on LB/kanamycin plates and grown overnight. Colonies that grew on the 
selective media were screened for the appropriate sized insert by direct colony PCR using 
an AceKI-1 specific primer (3’ACEKIXHO) and a vector specific primer (T7 Promoter) 
and by restriction enzyme digest {BamW 1 and Xliol) of plasmid DNA. Miniprep plasmid 
DNA from AceKI-1 positive colonies was subsequently subcloned into E. coli strain 
BL21 (pLysS) cells (Stratagene) for optimization of expression. Cells were plated on 
LB/kanamycin plates and individual colonies screened by PCR for presence of AceKI-1 
cDNA. 

A colony of transformed BL21 (pLysS) E. coli with the rAceKI-1 :pET28a insert 
was placed in a 50 mL culture of LB/kanamycin media and incubated at 37°C 250 RPM. 
Log phase cultures (OD60o = 0.6 - 1.0) were induced by the addition of isopropyl-f3-D- 
thiogalactopyranoside (1PTG; Labscientific Inc., Livingston, NJ) at a 1 mM final 
concentration and incubated for 3 hr with continuous shaking at 37°C. One milliliter 
aliquots were removed at 0, 1,2, and 3 hr post induction, centrifuged, and resuspended in 
tricine SDS-PAGE sample buffer (4% SDS, 12% glycerol, 0.5 M Tris-HCl, pH 6.8, 
0.01% Coomassie brilliant blue G) for SDS-PAGE and immunoblotting (see below). 
SDS-PAGE and Immunoblotting : Aliquots from above protein expression culture were 
incubated for 15 min 37°C in SDS-PAGE buffer. Approximately 10 pg of protein from 
each time point was subjected to SDS-PAGE using a 13% polyacrylamide gel. One 
protein gel was stained with Coomassie stain (40% methanol, 10% acetic acid, and 0.1% 
Coomassie Brilliant Blue R250 [BIORAD]) for one hour and then destained with a 
solution of 30% methanol and 10% acetic acid for observation of increased protein 
expression by induced bacteria. A second protein gel was used for Western blotting via 
transfer to a 0.2 pm nitrocellulose membranes (BIO-RAD; Hercules, CA) by electro 
blotting at 100V for 1 hr at 4°C. The membrane was incubated overnight at 4°C with 
slow agitation in a 1:10,000 dilution of monoclonal HRP labeled antibody to the T7 tag, 
5% milk, 0.05% Tween in PBS. After three washes in PBS 0.1% Tween, bands were 
visualized using a chemiluminescent substrate (SuperSignal West Pico, Pierce; Rockford, 
IL) and auto radiographic film (Kodak). 
Recombinant AceKI-1 Protein Purification : A 2-liter culture of log-phase BL21 
(pLysS) cells containing the pET28a:rAceKI-l plasmid was induced as above with 1 mM 
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IPTG. At 3 hr post-induction the cells were iced for 5 min, centrifuged at 4°C 5,000 
RPM, and resuspended in 1/10 the original culture volume of binding buffer (5 mM 
Imidazole, 500 mM NaCl, 20 mM Tris-HCl pH 7.9). The solution was sonicated using a 
Branson 450 Sonifier (50% Duty cycle, output 2) and centrifuged at 13,000 RPM for 20 
min at 4°C to separate soluble and insoluble fractions. The soluble supernatant from the 
induced cell lysate was applied to a Hi-Trap (Amersham Pharmacia Biotech AB; 
Uppsala, Sweden) 5 mL bed volume nickel resin affinity column charged with 50 mM 
NESCE at 25°C and equilibrated with binding buffer. The column was washed with a 60 
mM imidazole buffer and eluted with 1 M imidazole buffer (Novagen His-Bind Buffer 
Kit). Approximately 500 ng of partially purified protein and protein standards 
(GIBCO/BRL) were analyzed by SDS/PAGE and Western blotting, as described above. 
Following nickel resin affinity chromatography, the partially purified recombinant 
protein was subjected to reverse-phase HPLC using a Cis column (Vydac; Hesperia, CA). 
The bound protein was eluted with a linear gradient of 0-60% acetonitrile in 0.1% TFA. 
Individual peaks of protein as detected by absorbance at 214 nm were collected and 
assayed for serine protease inhibitory activity (as described below). 
Recombinant Protein Analysis : An aliquot from rpHPLC was subjected to 
Electrospray Ionization Mass Spectrometry (ESMS) using a Micromass Q-Tof mass 
spectrometer by the William Keck Foundation Biotechnology Resource Laboratory at 
Yale School of Medicine. Electrospray ionization Mass Spectrometry (ESMS) is used to 




An aliquot from rpHPLC was sent to the William Keck Foundation 
Biotechnology Resource Laboratory for amino acid analysis. A Beckman Analyzer was 
used to determine the molar concentration of the purified inhibitor. This molar 
concentration was used to characterize rAceKI-l’s inhibitory kinetics, see below (58). 
Assays of Protease Inhibition : Single stage chromogenic kinetic assays were used to 
characterize the inhibitory activity of r-AceKI-1 against six serine proteases (59). 
rAceKI-1 was preincubated with each of the enzymes listed below for 15 min at 25°C 
followed by addition of the appropriate chromogenic substrate. In a total volume of 200 
pi in individual wells of a 96-well microtiter plate, the concentration (expressed as final 
concentrations) of enzyme/substrate were as follows: porcine pancreatic elastase (1.5 nM; 
Sigma Aldrich, St. Louis, MO)/ Suc-Ala-Ala-Pro-Ala-pNA (250 pM; Bachem, Torrence, 
CA); human neutrophil elastase (7.5 nM; Calbiochem, La Jolla, CA)/ Elastase Substrate 1 
(250 pM; Calbiochem); bovine pancrease a-chymotrypsin (3 nM; Sigma)/ Suc-Ala-Ala- 
Pro-Phe-pNA (200 pM, Bachem); bovine pancrease trypsin (4 nM; Sigma)/ S2302 (250 
pM; DiaPharma, West Chester, OH); factor Xa (1.0 nM, Sigma)/ S2765 (250 pM; 
DiaPharma); a-thrombin (0.5 nM; Sigma)/ S2238 (250 pM; DiaPharma). The kinetic 
rate of substrate hydrolysis (mOD/min) at 405 nM was measured over 5 min using a 
kinetic microplate reader (MRX HD; Dynex Laboratories, Chantilly, VA). Results were 
expressed as percent inhibition of rAceKI-1 activity using the following formula: percent 
inhibition = 1 - inhibited rate/uninhibited rate x 100. 
By using the single-stage chromogenic assay described above, we then 
• ••••• He 
established the apparent equilibrium dissociation inhibitory constant, K, (60,61), for 
purified rAceKI-1 against pancreatic elastase, human neutrophil elastase, chymotrypsin. 

and trypsin. In each microtiter well, varying rAceKI-1 concentrations were incubated for 
15 min with a fixed enzyme concentration, as above. Substrate was then added at a final 
concentration of five times the Kin and the initial rate (mOD/min) of substrate hydrolysis 
over 5 min was measured at 405 nm. This assay was repeated using increasing amounts 
of inhibitor and the ratio of inhibited velocity (V() to uninhibited velocity (V0) was 
plotted against the corresponding rAceKI-1 concentration. All experiments were 
performed in triplicate, and these kinetic data were fit to the Morrison equation for the 
■ ••• • ^ 
analysis of tight binding protease inhibitors to derive the K, for rAceKI-1 (62,63). 
Purification of native AceKI: In collaboration with Dr. Richard Bungiro at Yale, 
soluble extracts from 200 adult A. ceylanicum (see above preparation) were applied to a 
300x7.5 mm size-exclusion chromatography column (Bio-Sil TSK-125; BIO-RAD, 
Hercules, CA) that was equilibrated with 50 mM Tris-HCl, pH 7.5 and 0.2 M NaCl. 
Individual fractions were tested for serine protease inhibitory activity, as described 
above, and active fractions were pooled. The molecular mass of the presumed native 
AceKI was estimated by extrapolation from a standard curve (logmoiecuiar mass vs. retention 
factor [Rf]) constructed from the elution profile of a mixture of protein standards (BIO¬ 
RAD) with known molecular masses. 
Following size-exclusion chromatography, the pooled active fractions were 
subjected to reverse-phase HPLC using a Cjg column (Vydac; Hesperia, CA). The 
bound protein was eluted with a linear gradient of 0-60% acetonitrile in 0.1% TFA. 
Individual peaks of protein as detected by absorbance at 214 nm were collected and 
reassayed for serine protease inhibitory activity. 
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Native Protein Analysis : An aliquot of rpHPLC purified native AceKI-1 was subjected 
to matrix-assisted laser desorption ionization mass spectroscopy (MALDI-MS) by the 
William Keck Foundation Biotechnology Resource Laboratory at Yale School of 
Medicine to determine molecular mass. MALDI-MS uses a research grade, VG TOFspec 
SE instrument equipped with delayed extraction and a reflectron. Masses can he 
determined with an average mass accuracy of ±0.1% with external calibration (64). 
To confirm that the purified native protein corresponded to rAceKI-1, a sample 
was sent to the William Keck Foundation Biotechnology Resource Laboratory at Yale 
School of Medicine for NFL-terminal amino acid sequencing. The amino terminal 
sequencing is earned out on an Applied Biosystems sequencer equipped with an on-line 




Cloning of AceKI-1 cDNA Sequence : To obtain initial cDNA sequence of AceKI-1 
Lisa Harrison used a sense strand PCR primer corresponding to the nematode spliced 
leader (SL) sequence present in the 5’ region of many nematodes mRNAs (51-53) and a 
degenerate antisense strand primer homologous to a conserved region (CKDGFYRD) 
located near the carboxy-terminus of Ascaris-type inhibitors (42). Using these primers, a 
cDNA fragment of approximately 250 bp was amplified from total adult Ancylostoma 
ceylanicum RNA. Translated amino acid sequence of the initial AceKI-1 cDNA 
demonstrated homology to members of the Kunitz family of serine protease inhibitors 
(see discussion), including tissue factor pathway inhibitor and the silkworm 
chymotrypsin inhibitor (see Figure 5). 
The partial cDNA contained the spliced leader and the 5’ ATG initiation codon, 
but not the 3’ poly(A) tail. I began my project by isolating the 3’ end of AceKI-1 from 
adult A. ceylanicum using RT-PCR and a 3' RACE technique with a newly designed 
internal primer and an oligo (dT) primer. This yielded an approximately 300 bp 
fragment. Three separate 3’ end clones were sequenced and contained identical 
overlapping sequence with the initial cDNA. The full length AceKI-1 cDNA contains an 
open reading frame of 252 nucleotides (see figure 4). The translated AceKI-1 amino acid 
sequence was analyzed using the SignalP Program, a signal peptide prediction program. 
The SignalP Program strongly predicted a 16 amino acid signal sequence with the 
cleavage site of the translated protein to be located between residues 16 and 17 (C-A) of 
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Figure 4 : AceKI-1 nucleotide sequence and deduced amino acid sequence. 
AceKI-1 (in bold) consists of 252 base pairs with a deduced protein sequence of 82 amino acids. 
Initiation of translation was based on the first ATG downstream of the nematode SL sequence. 
The protein has a 16 amino acid signal sequence (lightly shaded) whose cleavage site was 
predicted between residues 16 (C) and 17 (A)(underlined). The mature protein is 68 amino acids 
followed by a TAA stop codon (darkly shaded). Interestingly, the AceKI-1 nucleotide sequence 
corresponding to the initial 3’ primer (CKDGFYRD)(circled) has only 14 of 22 matching 
nucleotides. The complete cDNA was submitted to GenBankIM with accession number 
AF172651. 
The translated sequence of the AceKI-1 cDNA predicts a mature protein of 68 amino 
acids with a MW of 7889 Da and a pi of 6.79. 
Homology of AceKI-1: Analysis of the translated amino acid sequence using the 
BLAST algorithm revealed AceKI-l’s homology to other Kunitz-type inhibitors, 
including the chymotrypsin inhibitor from the silkworm Bombyx mori (65), a trypsin 
inhibitor from Ancylostoma caninum (36), and multiple domains of human and rat tissue 
factor pathway inhibitor (36,66). The location of cysteine residues in AceKI-1 (see 
figure 5) suggest that this is the first Kunitz-type serine protease inhibitor identified from 
this species of human hookworm (see discussion). 
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SILKWORM CHYMOTRYPSIN INHIBITOR II - Bombyx mori 
Score = 64.8 bits (155), Expect = 8e-ll, Identities = 26/47 (55%), Positives = 33/47 
(69%), Gaps = 1/47 (2%) 
AceKI-1: 8 KLTDEERCNAPTHLDGPQCMAFFKRYTYNKEKKQCEEFVYGGCRPSPNNFETMEECKKTCVK 
K T + C GP C A+ K Y+YN++ K+CEEF+YGGC+ + N F+T + EC++ C+K 
SCI-II: 2 KPTTKPICEQAFGNSGP-CFAYIKLYSYNQKTKKCEEFIYGGCKGNDNRFDTLAECEQKCIK 
CATRIN - Kunitz-type Trypsin Inhibitor - Ancylostoma caninum 
Score = 60.5 bits (144), Expect = le-09, Identities = 30/80 (37%), Positives = 45/80 
Gaps = 9/80 (11%) 
AceKI-1 : 4 LLVVLLCVAIAYCAEEAGKKLTDEERCNAPTHLDGPQCMAFFKRYTYNKEKKQCEEFVYG 63 
+L++ +C AIA A + + EC +C AF KR+ Y+ + +C+ F+YG 
Catrin: 11 VLLLFVCFAIASEARRDIRCVQAVEAC- -KCRAFMKRWAYDVTENKCKPFMYG 61 
AceKI-1 : 64 GCRPSPNNFETMEECKKTCV 83 
GC + NNFET ECK+ CV 
Catrin: 62 GCGGTDNNFETEAECKRICV 81 
TISSUE FACTOR PATHWAY INHIBITOR BETA (TFPI)- Homo sapiens 
Score = 63.6 bits (152), Expect = 2e-10, Identities = 26/48 (54%), Positives = 34/48 
(70%), Gaps = 1/48 (2%) 
AceKI-1: 21 DGPQCMAFFKRYTYNKEKKQCEEFVYGGCRPSPNNFETMEECKKTCVK 68 
DGP C A KR+ +N +QCEEF+YGGC + N FE++EECKK C + 
TFPI : 60 DGP-CKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTR 106 
AceKI-1: 25 
TFPI : 134 
CMAFFKRYTYNKEKKQCEEFVYGGCRPSPNNFETMEECKKTC 66 
C + RY YN + KQCE F YGGC + NNFET+EECK C 
CRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNIC 175 
TISSUE FACTOR PATHWAY INHIBITOR PRECURSOR (TFPI) - Rattus rattus 
Score = 64.8 bits (155), Expect = 8e-ll, Identities = 26/47 (55%), Positives = 33/47 
Gaps = 1/47 ( 
AceKI-1 : 21 
TFPI: 59 
AceKI-1 : 25 
TFPI: 133 
AceKI-1 : 14 
TFPI : 222 
DGP C A + Y +N QCEEF+YGGCR + N F+T+EEC+KTC+ 
66 
C F RY YN + KQCE+F YGGC + NNFET+EEC+ TC 
CNAPTHLDGPQCMAFFKRYTYNKEKKQCEEFVYGGCRPSPNNFETMEECKKTCVK 68 
CP D C A KR+ YN +C +F Y GC + NNF T ++C + C K 
Figure 5 : AceKI-1 amino acid sequence homology. 
Initial BLAST results revealed AceKI-l’s homology to Kunitz-type inhibitors including a 
chymotrypsm inhibitor from the silkworm Bombyx mori, Catrin, two domains of human Tissue 
Factor Pathway Inhibitor, and all three domains of 7?. rattus Tissue Factor Pathway Inhibitor. 
Catrin, a trypsin inhibitor previously cloned from A. caninum, is the only other Kunitz-type 
protease inhibitor reported to date from adult hookworms. The cysteine residues involved in 
disulfide bridges are shaded in light gray. The P| reactive site residues are bold faced and 
underlined, along with the postulated P| methionine of AceKI-1 (see discussion). 
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Expression and Purification of Recombinant AceKI-1 : The cDNA fragment 
corresponding to the mature 68 amino acid AceKI-1 was cloned in-frame into the 
pET28a prokaryotic expression vector. Lysates of induced cells were separated using 
SDS-PAGE under non-reducing conditions. After Coomassie staining, no bands were 
visualized that would suggest an obvious increase in protein expression following 
induction. Western blots, however, using a monoclonal antibody against the pET28a 
fusion protein T7 Tag confirmed the presence of the rAceKI-1 fusion protein in the 
soluble fraction. 
Having established that AceKI-1 was capable of being expressed in E. coli, the 
pET28a-rAceKI-l fusion protein was induced in large-scale culture at an estimated 
concentration of 0.5 mg/L. Induced cell lysates were applied to a nickel resin affinity 
column. The partially purified recombinant protein was subjected to reverse-phase High 
Pressure Liquid Chromatography using a Cis column. The bound protein was eluted with 
a linear gradient of 0-60% acetonitrile in 0.1% TFA. Individual peaks were tested for 
serine protease inhibition. Recombinant AceKI-1 eluted at an acetonitrile concentration 
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Figure 6 : Purification of recombinant AceKI-1 by reversed phase HPLC 
Following nickel resin chromatography, the partially purified recombinant protein was subjected 
to reversed-phase HPLC using a C]8 column. The bound protein was eluted with a linear gradient 
of 0-60% acetonitrile in 0.1% TFA. Individual peaks were tested for inhibition of chymotrypsin 














The purified recombinant protein was further characterized by ESMS (see Figure 7), and 
results show a predominant peak with molecular mass of 11,293 Daltons, compared to a 
predicted molecular mass of 11,451 Daltons [mature protein (7889 Da) + fusion tag 
(3562 Da)], a 1.4% difference. Quantitative amino acid analysis was performed on the 
rpHPLC purified protein in order to determine the molar concentration of the protein 
sample. 
ACEKI1 
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Figure 7 : Electrospray Ionization Mass Spectrometry (ESMS) of recombinant AceKI-1. 
The William Keck Foundation Biotechnology Resource Laboratory at Yale School of Medicine 
subjected an aliquot from rpHPLC representing purified rAeeKI-1 to ESMS. Results show a 
predominant peak with molecular mass of 11,293 Da., compared to a predicted molecular mass of 
of 11.451 Da. 
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Serine Protease Specificity : The selectivity of rAceKI-1 was examined against 6 serine 
proteases, and inhibitory activity was demonstrated against chymotrypsin, pancreatic 
elastase, human neutrophil elastase, and trypsin. At a molar ratio of 2:1, rAceKI-1 
:enzyme, there was no detectable inhibition of factor Xa or thrombin. We then used 
single stage chromogenic assays to measure the rate of enzyme hydrolysis of 
chromogenic substrate in the presence of increasing concentrations of rAceKI-1. These 
kinetic data were fit to the Morrison equation developed for the analysis of tight binding 
inhibitors, generating an apparent equilibrium dissociation inhibitory constant (AT, ) for 
porcine pancreatic elastase chymotrypsin, human neutrophil elastase, and trypsin (see 
Table 1 and Figures 8). 
Table 1 
Enzyme -kT- 
Porcine pancreatic elastase 277 pM +/- 71 pM 
Chymotrypsin 485 pM +/- 102 pM 
Human neutrophil elastase 1.06 nM+/- 427 pM 
Trypsin 21 nM +/- 3.8 nM 











4 6 8 10 
rAceKI-1 (nM) 
Figure 8 : Inhibitory Kinetics of recombinant AceKI-1. 
rAceKI-1 in increasing concentrations was incubated with trypsin, chymotrypsin, pancreatic 
elastase, and neutrophil elastase followed by addition of chromogenic substrate. The velocity of 
substrate hydrolysis in the presence of rAceKI-1 (V,) and the absence of rAceKI-1 (V0) was then 
measured as described in the Materials and Methods. The observed velocity data (solid lines) 
was tit to the Morrison equation for the evaluation of tight binding inhibitors. V,/V0 = [E - I 
A/*] + [(I + Ki* - E)2 + 4A,*E]i/2/2E where E and 1 are the total amount of enzyme and inhibitor, 
respectively, and K, is the apparent equilibrium dissociation inhibitory constant for purified 




Life cycle Stage Specificity: Having characterized rAceKI-l’s inhibitory activity, I 
wanted to determine whether a similar native activity was present in different 
developmental stages of A. ceylcinicum. Soluble protein extracts from both infective third 
stage (L3) Ancylostoma ceylcinicum larvae and adult A. ceylcinicum were therefore tested 
for inhibitory activity against pancreatic elastase, human neutrophil elastase, trypsin, and 
chymotrypsin. While adult extracts inhibited all four enzymes, L3 extracts only inhibited 
human neutrophil elastase (see figure 9). These data suggest that AceKI-1 is not 
produced in significant amounts by the L3 stage ofhookwonns (see discussion). 
A. ceylcinicum Adult A. ceylcinicum Infective 
Extracts (2 pg) Larval Stage Extracts (2 jug) 
Chymotrypsin (3 11M) 87%a 4% 
Trypsin (4 nM) 80% 14% 
Pancreatic Elastase 77% 16% 
(1.5 nM) 
Human Neutrophil 79% 59% 
Elastase (7.5 nM) 
A Percent inhibition of each enzyme by stage specific soluble protein extracts 
Figure 9 : Lifecycle stage specificity of AceKI-1 activity. 
Soluble protein extracts from both adult and L3 A. ceylcinicum demonstrate inhibitory activity 
against human neutrophil elastase, but L3 extracts have virtually no significant inhibit activity 
against chymotrypsin, trypsin and pancreatic elastase. This suggests that AceKI-1 is expressed 
only during specific stages in the hookworm lifecycle (see discussion). 
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Excretory and Secretory (ES) Products: After demonstrating a similar inhibitory 
activity to AceKl-1 in adult Ancylostoma ceylanicum extracts, 1 wanted to determine if a 
similar activity was present in ES products. Adult A. ceylanicum ES products (as 
described in Methods) were therefore tested for inhibitory activity against pancreatic 
elastase, trypsin, and chymotrypsin. The results demonstrate that adult ES products 
effectively inhibited pancreatic elastase (79%), chymotrypsin (66%), and trypsin (56%) 
compared to RPMI media/hamster sera alone (see Figure 10) 
Figure 10 : Inhibitory activity of native AceKI-1. 
ES products from adult A. ceylanicum are compared to soluble protein extracts of adult A. 
ceylanicum for their respective inhibition of pancreatic elastase (1.5nM), trypsin (4nM), and 
chymotrypsin (3nM). Both adult A. ceylanicum extracts and E/S products inhibit pancreatic 
elastase, chymotrypsin and trypsin. The inhibitory profile of native AceKI-l is therefore similar 
to that of recombinant AceKI-1. Data illustrated as percent activity (1- percent inhibition) 
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Species Specificity: Equal amounts of soluble protein extracts from adult hookworms 
Ancylostoma ceylanicum, Ancylostoma caninum, and Necator americanus were screened 
for inhibitory activity against pancreatic elastase, trypsin, and chymotrypsin. All these 
hookworm species contained comparable inhibitory activity against these three enzymes 
(see figure 1 1). Chymotrypsin was inhibited by A. ceylanicum (92%), A. caninum (91%), 
and N. americanus (94%); trypsin was inhibited by A. ceylanicum (75%), A. caninum 
(88%), and N. americanus (90%); pancreatic elastase was inhibited by A. ceylanicum 
(95%), A. caninum (93%), and N. americanus (89%). Assuming that this inhibitory 
activity is due to AceKI-1, these data suggest that AceKI-1 is broadly conserved across 
evolutionary distinct hookworm species. 




Figure 11 : Conservation of AceKI-1 inhibitory activity across hookworm species. 
5 pg of soluble protein extracts from A. ceylanicum, A. caninum, and N. americanus were 
screened for activity against pancreatic elastase (1.5nM), trypsin (4nM), and chymotrypsin 
(3nM). Chymotrypsin, trypsin and pancreatic elastase inhibitory activity is present in all 
three species, suggesting that inhibition of these three serine proteases is broadly conserved. 
Purification of native AceKI: In order to prove that the activity in soluble protein 
extracts corresponds to the AceKI-1 cDNA gene product, with the help of Dr. Richard 
Bungiro, I purified the native inhibitor from adult A. ceylanicum. Fractions from size 
exclusion chromatography of soluble adult hookworm extracts were measured for 
inhibitory activity against chymotrypsin and elastase. The activity eluted at an estimated 
weight of approximately 9 kDa, based on extrapolation from a standard curve constructed 
with proteins of known molecular mass. The pooled samples of chymotrypsin and 
elastase inhibitory activity were then subjected to lpHPLC on a Cig column. All of the 
anti-chymotrypsin and anti-elastase activity eluted in a single protein peak at an 
acetonitrile concentration of approximately 26% (see figure 12). Likewise, the rAceKI-1 
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Figure 12 : Purification of native AceKI-1 by reversed phase HPLC 
Following size exclusion chromatography, the partially purified protein was subjected to 
reversed-phase HPLC using a C18 column. The bound protein was eluted with a gradient of 0- 
60% acetonitrile in 0.1% TFA. Individual peaks were tested for inhibition of chymotrypsin and 














The native protein was further characterized by MALDI-MS (see figure 13), which 
revealed a single major peak with a molecular weight of 7882 Daltons, compared to the 
predicted molecular weight of 7889 Da based on the translated sequenceof the AceKI-1 
cDNA. This difference of 7 Da (0.08%) is within the range of error for the MALDI-MS 
measurements of protein mass. 
100 7882.32 6.28e3 
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Figure 13 : Matrix-Assisted Laser Desorption Ionization Mass Spectroscopy (MALDI- 
MS) of native AceKI-1. 
The William Keck Foundation Biotechnology Resource Laboratory at Yale School of Medicine 
subjected an aliquot from rpHPLC representing purified native AceKI-1 to MALDI-MS. Results 
show a predominant peak with molecular mass ot 7,882 Da., compared to a predicted moleculai 
mass of 7889 Da. 
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In order to confirm that the native protein was, in fact, AceKI-1, the purified inhibitor 
was submitted to the William Keck Foundation Biotechnology Resource Laboratory at 
Yale School of Medicine for NFL-terminal sequence. The first eight NFL-terminal amino 
acid residues from the purified protein were identical to the first eight amino acid of the 




Hookworms, blood feeding intestinal nematodes, infect more than one billion 
people in the developing world. The most significant clinical complication from 
hookworm infection is iron deficiency anemia, resulting from chronic gastrointestinal 
blood loss. Women and children often have lower total body iron stores and are therefore 
most susceptible to developing hookworm anemia. In children, heavy infection is 
associated with lower scores on intelligence tests and decreased scholastic performance. 
Current strategies targeting hookworm disease revolve around the use of anthelminthics. 
With growing concern of drug resistance and drug toxicity, the search for alternative 
control tactics continues. Dr. Cappello’s laboratory is working to identify novel protease 
inhibitors from adult hookworms that aid in parasite survival and contribute to the 
pathogenesis of hookworm anemia. Ultimately, interfering with these parasite virulence 
factors may serve as a novel therapeutic strategy to alleviating hookworm disease. 
I report here the first Kunitz-type serine protease inhibitor isolated from adult 
Ancylostoma ceylanicum, a blood feeding hookworm. The translated sequence of the 
Ancylostoma ceylanicum Kunitz-type Inhibitor 1 (AceKI-1) cDNA predicts a mature 
protein of 68 amino acids with a MW of 7889 Da. The AceKI-1 cDNA was cloned into a 
prokaryotic expression vector and recombinant AceKI-1 (rAceKI-1) was purified using 
nickel resin affinity and rpHPLC chromatographies. The molecular weight of rACeKI-1 
was confirmed by mass spectroscopy. Single stage chromogenic assays revealed that 
rAceKI-1 is a potent inhibitor of the serine proteases chymotrypsin (K)* = 485 pM), 
porcine pancreatic elastase (K,* = 277 pM), and human neutrophil elastase (K,* = 1.06 
nM). The inhibitor demonstrates weaker inhibitory activity against trypsin (AT,* = 21nM) 

39 
and no detectable activity against coagulation proteases factor Xa and thrombin. After 
identifying this biological activity in vivo, we purified native AceKI-1 (nAceKI-1) from 
soluble extracts of adult Ancylostoma ceylanicum using size exclusion and rpHPLC 
chromatographies. Yale’s Keck Foundation Biotechnology Resource Laboratory verified 
the native protein’s molecular weight using mass spectroscopy. NFL-terminal amino acid 
sequencing of nAceKI-l’s first eight residues confirmed identity of the native and 
recombinant proteins. 
AceKI-1 is the first Kunitz-type protease inhibitor isolated from Ancylostoma 
ceylanicum. As discussed earlier, serine protease inhibitors are divided into families 
based upon the configuration of disulfide bridges and the sequential location of each 
reactive site (47). The pattern of intrachain disulfide bridges is conserved within 
families, helping to categorize newly identified protease inhibitors. Some of the families 
include the Kunitz (Bovine Pancreatic Trypsin Inhibitor) Family, the Kazal (Pancreatic 
Secretory Trypsin Inhibitor) Family, the Bowman-Birk Inhibitor Family, the Serpins, and 
the Ascaris Trypsin Inhibitor Family. 
Protease inhibitors are ubiquitous in nature, generally functioning to prevent 
undesired proteolysis. Most protease inhibitors target only proteases belonging to a 
specific class. Their action relies on presenting an endogenous peptide bond, a reactive 
site, as a substrate to the target enzyme and forming a classic lock and key interaction. 
Protease inhibitors are divided into classes by the mechanistic action of their inhibition; 
some inhibit carboxyl, metalo and sulfhydryl proteinases, and others inhibit serine 
protease. Serine protease inhibitors are the best characterized and understood, and 
although there are many heterogeneous subfamilies, they do have a similar mechanism of 
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action. The reactive site of each inhibitor interacts with the respective active site of its 
associated enzyme. A stable complex is formed and hydrolysis occurs very slowly as if 
the coupling was being maintained at equilibrium. Each reactive site residue, denoted as 
Pi, generally designates the specificity of a given inhibitor for a particular protease (67). 
In order to categorize and characterize a novel protease inhibitor we use BLAST 
searches looking for amino acid sequence homology to previously described inhibitors. 
All members of the Ascaris family, for example, share five intramolecular disulfide 
bridges (68) and 30-40% amino acid sequence identity (69). Kunitz inhibitors are 
approximately 60 amino acid residues in length, are generally tight binding inhibitors 
(70), and their six cysteine residues fonn three disulfide bridges in the characteristic 
pattern : 1-6, 2-4, 3-5 (71). rAceKI-1 demonstrates strong homology to members of the 
Kunitz family based on its spacing pattern of cysteine residues and postulated Pi reactive 
site (see figure). By examining the amino acid sequence and comparing it to other 
protease inhibitors, we can postulate its mechanism of inhibition of chymotrypsin, 
pancreatic elastase, human neutrophil elastase, and trypsin. 
In order to elucidate AceKI-l’s mechanism of inhibition, we will first look at the 
reactive site amino acid residue and the structural interactions of other Kunitz inhibitors. 
Bovine Pancreatic Trypsin Inhibitor (BPTI) was the first Kunitz inhibitor to be 
characterized on a structural level and serves as a model for other Kunitz inhibitors. 
Studies of the molecular structure of BPTI’s reactive site and side chain interactions have 
helped to explain why amino acids in this region determine the specificity by which 
Kunitz inhibitors bind proteases. The tertiary structure of BPTI suggests the reactive site 
is an external loop held stable and rigid by interactions with its own core molecule and an 
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additional minor loop (72). This external loop contains the reactive site, P| residue, 
where primary interaction occurs with the cognate protease’s catalytic site, the Si 
principal specificity cavity (73) (see figure 14). This inhibitor:protease complex is 
stabilized by van der Waals interactions between the carbonyl carbon of the Pi residue 
and the nucleophilic oxygen of the 
catalytic protease side chain (74). 
Water molecules fill the grooves as 
permitted, strengthening the 
interaction with hydrogen bonds. This 
reactive site loop and active site cleft 
form a tight interaction with little free 
energy, thereby requiring a high 
activation energy for hydrolysis and 
dissociation (75). The scissile bond of 
these tight binding inhibitors, 
therefore, remains intact as it 
undergoes slow hydrolysis (77). The 
Figure 14 : TFPI Domain 1 (76) 
This diagram, based on the secondary structure of 
BPTI, illustrates the ammo acid sequence of TFPI 
domain 1, which is homologous to AceKI-1. Three 
cysteine-cysteine disulfide bonds between can be 
seen as is the protease inhibitor’s external loop, 
residues 30-50. At location 36 is the P| lysine. The 
conserved GPC, P2 - P4, should be noted and will be 
seen discussed below. 
interaction between the Pi residue and the Si cleft is determined by the amino acids in the 
area of the reactive site; specifically, the side chains of the Pi residue itself and those of 
its surrounding amino acids, and their ability for polar interaction. 
Based on the selective interactions of reactive site residues and their cognate 
enzyme’s catalytic site, we expect proteases to bind preferentially to certain P, amino 
acid residues. For example, chymotrypsin is selective for peptide bonds on the carboxyl 
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side of large hydrophobic or aromatic residues. Chymotrypsin has a large SI cleft with a 
neutral serine and can bond well with aromatic side chains of phenylalanine or a 
hydrophobic methionine (73). In general, the following Pi residues commonly interact 
with the respective proteases: tyrosine, phenylalanine, leucine, and methionine with 
chymotrypsin; leucine and arginine with trypsin; leucine, methionine, and valine with 
elastase (78). The nature of interaction between proteases and reactive sites will 
determine the overall specificity; resultingly, strong inhibition of chymotrypsin and 
elastase tends not to be seen concurrently with strong inhibition of trypsin. AceKI-1 ’s 
interaction with chymotrypsin, however, is therefore consistent with its postulated PI 
methionine (discussed below). 
Understanding how reactive site residues and cognate enzymes interact illustrates 
why the activity of Kunitz inhibitors depends upon the properties of their Pi amino acid 
residues. BPTI, for example, a strong inhibitor of trypsin, has a Pi lysine that weakly 
interacts with chymotrypsin. Carboxamidomethylation and reduction of the primary 
disulfide bond eliminates the chymotrypsin activity while retaining the trypsin activity, 
presumably by altering bonding interaction between the catalytic sites (79,80). 
Chymotrypsin inhibitors have been identified from cobra venom of Naja naja naja, the 
silkworm Bonibvx mori, and venom of Vipera ammodytes and their Pi residues are 
phenylalanine, phenylalanine, and leucine, respectively (81). A Kunitz-type trypsin 
inhibitor from Fasciola hepatica was identified with Pi leucine (82). Leucine is not 
characteristically complexed with trypsin, which might explain why this inhibitor has a 
high dissociation constant and is not tight binding. 
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Comparing protease inhibitor homologues from humans and pigs demonstrates 
the role that the reactive site amino acid residue plays in determining the specificity of 
interaction between inhibitors and cognate enzymes. Human Inter-a-Trypsin Inhibitor 
(HITI) is a well-characterized bidomain Kunitz-type inhibitor of trypsin found in many 
species of mammals. HITI’s C-terminal domain, which inhibits trypsin strongly and 
chymotrypsin weakly, has arginine at its Pi residue (83). The N-terminal domain has a Pi 
methionine, weakly inhibits polymorphonuclear (PMN) granulocyte elastase, and has no 
activity against chymotrypsin and pancreatic elastase (84). In comparison, bovine Inter- 
a-Trypsin Inhibitor (BITI)’s C-terminal domain is similar in sequence and activity to 
HITI; however, its N-terminal Pi leucine functions as a strong inhibitor of PMN 
granulocyte elastase, pancreatic elastase and chymotrypsin (85). The N-terminal domain 
of HITI and BITI exemplify how differences in the reactive site amino acid affect the 
specificity of individual protease inhibitors. 
Other studies demonstrate that substitutions or mutations of the P| amino acid 
residue can alter activity of a homologous protease inhibitor. BPTI derivatives with 
methionine and valine replacing the Pi residue lysine are strong inhibitors of 
chymotrypsin, and chymotrypsin and elastase, respectively (85/72). Mutation of the P| 
lysine in Bovine Trypsin Kallikrein Inhibitor to phenylalanine and tryptophan decreased 
activity against trypsin and greatly increased inhibition of chymotrypsin (86). 
Mutagenesis of the Pi arginine in Alzheimer’s (I-Amyloid Precursor Protein (APP-KD) to 
valine changed a trypsin and chymotrypsin inhibitor to a strong inhibitor of human 
neutrophil elastase (87). Notable in this study was that the small hydrophobic valine did 
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not confer inhibitory activity against chymotrypsin. Altering the amino acid residue at 
the reactive site can therefore significantly influence overall inhibitor specificity. 
In general, the Pi residue plays a crucial role in the specificity of cognate enzyme 
binding. Although we have not determined the active site of rAceKI-1 experimentally, 
by comparing it to BPTI, human TFPI, and other Kunitz inhibitors, we can assign the 
methionine as the probable P| residue (see figure 15). As mentioned, methionine is a 
large hydrophobic residue that binds well to chymotrypsin and has been shown to fit into 
the Si cleft of elastase as well (88). Interestingly, rAceKI-1 is also a weak inhibitor of 
trypsin. Based on the tight binding kinetics of rAceKI-l’s protein inhibition, it is 
surprising that it would have such broad protease inhibitory capacity. There are reported 
serine protease inhibitors that have a similar broad spectrum of activity. Ecotin, a unique 
inhibitor of chymotrypsin, elastase, and trypsin from E. coli has a Met as its reactive 
residue (78). Ecotin’s unusual primary structure does not demonstrate similarities to those 
in common families of protease inhibitors. Human ai-proteinase inhibitor inhibits 
elastase and chymotrypsin more potently than trypsin, presumably due to the presence of 
a methionine occupying its Pi position (89). Streptomyces Subtilisin Inhibitor, a 
homologue of Kazal type inhibitors, has a Pi methionine and potently inhibits 
chymotrypsin and trypsin (90). Although such broad activity protease inhibitors exist, 
AceKI-1 is the first identified from the Kunitz family. 
To account for AceKI-1’s unique inhibitory properties, it is important to closely 
compare its amino acid sequence to those of other Kunitz inhibitors (see figure 15). 
AceKI-1 ’s six cysteine residues clearly align with those of other Kunitz inhibitors, as 
does the predicted P] methionine at position 15. As has been shown above, a methionine 
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residue at position 15 is consistent with inhibition of chymotrypsin and elastase, but a 
large hydrophobic residue does not generally interact with trypsin, and thus does not 
explain the weaker trypsin inhibitory activity. To explain this broader inhibitory 
activity, we look at other areas of interaction. The amino acid residues 6-13 (P10-P3) in 
Kunitz inhibitors have been shown to play a major role in chemical recognition and 
binding interactions with proteases (70). Substitutions in this region rarely affect the 
conformation of the external loop but can change the inhibitor’s specificity; however, 
only the side chains of the Pi residue, position 15, strongly contact the binding site of the 
serine protease. Compared to other Kunitz protease inhibitors, AceKI-1 does have a 
unique sequence in the binding domain of residues 12-15, containing a GPQC instead of 
the usual GPC. The addition of glutamine at position 13 might play a role in this 
P2P1P1 
H-TFPI C AFKADDGP 
Rb-TFPI C AMKVDDGP 
Rt-TFPI C AMKAEDGP 
Mo-TFPI C AMKADDGP 
rAceKI-1 CNAPTHLDGP1 
BPTI C LEPPYTGP 
ITI/H C QLGYSAGP 










P3 P2 Pi 
Q C M 
30 
Pi'P2'P3'Pf 
A F F K 
38 51 55 
Figure 1 5 : Alignment of rAceKl-1 amino acid sequence with other Kunitz-type inhibitors. 
Human tissue factor pathway inhibitor (TFPI) (66), rabbit TFPI (Rb-TFPI) (66), rat TFPI (Rt- 
TFPI) (66), mouse TFPI (Mo-TFPI) (91), bovine pancreatic trypsin inhibitor (BPTI) (82), Human 
inter-alpha-trypsin inhibitor - domain 1 (ITI/H) (84), venom basic protease inhibitor - eastern 
green mamba (IVBB) (70), and Long-nosed viper chymotrypsin inhibitor - Viper ammodytes 
(LNVChyl) (82). The method for residue localization is demonstrated with rAceKI-1 showing 
P4-P4’. The P| residues at position 15, the reactive site, are bold faced. The six cysteine residues 
at positions 5, 14, 30, 38, 51, and 55, predicted to be involved in disulfide bridges, are shaded in 
light gray. The underlined amino acid residues 6-13 (Pio-P3) in Kunitz inhibitors have been shown 
to play a major role in chemical recognition and binding interactions with proteases. On the edge 
of this binding region the conserved GPC is shadowed, and the additional glutamine residue at 
position P3 and asparagine residue at position P12 are shaded in dark gray. 
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inhibitor’s more unique chemical recognition and target enzyme specificity. 
We have therefore postulated our Pi reactive site as a methionine and have 
discovered a unique additional glutamine residue in a generally conserved binding region. 
We hope to perform site directed mutagenesis at the position 15 methionine measure its 
inhibitory activity. It will be interesting to determine if, after changing the reactive site 
from methionine to lysine or arginine, chymotrypsin and elastase activity will be lost and 
the trypsin activity amplified. We also plan to structurally model this novel protease 
inhibitor to see if its additional glutamine residue might increase the area of interface in 
the inhibitor:protease complex providing increased stability and therefore broader 
activity. 
Serine proteases are ubiquitous in nature. As novel inhibitors are identified and 
their molecular structures and functions are characterized, it is possible to hypothesize as 
to their presumed role in vivo. In studying parasite derived protease inhibitors, similarly, 
many investigators have questioned what biologic role these proteins play in parasite 
survival. E. coli produce Ecotin, a periplasmic protein that inhibits chymotrypsin, 
elastase, and trypsin. These pancreatic proteases are all present in high concentrations in 
the natural environment of the organism leading to the hypothesis that Ecotin is required 
for E. coli to survive in the intestine (92). Similarly, the trypsin inhibitor from Fasciola 
hepatica is presumed to be involved in parasite survival (82). A pancreatic and 
neutrophil elastase inhibitor from the blood fluke Schistosoma mansoni has been 
suggested to protect the parasite from neutrophil mediated immune attack (93). We can 
likewise postulate that rAceKI-1 is required for protecting hookworm against host 
responses, especially in its natural intestinal environment. Interestingly, 
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immunohistochemistry performed on the intestinal nematode Ascaris suum, using 
antibodies to chymotrypsin and the Ascaris chymotrypsin inhibitor, demonstrated host 
chymotrypsin enzyme and Ascaris inhibitor complexes in sections of wonn muscle, eggs, 
sperm, and intestines (94). From these results one could argue either that Ascaris are 
removing host proteases from their environment for neutralization, or that these are 
endogenous proteases that play no role in parasite survival. We have identified AceKI-1 
in both adult hookworm extracts and ES products, implying its role is not simply 
endogenous to the wonn, but it is secreted or excreted into the parasite’s surrounding 
environment. AceKI’s inhibition of trypsin and chymotrypsin may therefore enable the 
parasite to survive the hydrolytic environment of the intestine, and its inhibition of 
neutrophil elastase might hinder the natural host immune response. By developing a 
rabbit antibody to rAceKI-1 and using immunohistochemistry to localize its site of 
production and storage in A ceylanicum, we hope to gain a better understanding of 
AceKI-l’s biologic role. 
While characterizing the role of secreted molecules in hookworm survival, 
scientists have questioned the importance of life cycle or stage specificity. The third 
stage (L3) infective larvae of Ancylostoma, for example, complete their developmental 
molts while in the host. It is hypothesized that Ancylostoma ES products contain 
molecules required for completion of these molts, as well as tissue invasion and evasion 
of the host immune response (95). These activities of tissue invasion and molting are 
stage specific and the translation of genes encoding such proteins may be up regulated 
only when developmentally required. We have shown that soluble protein extracts from 
adult A. ceylanicum inhibit chymotrypsin, trypsin, pancreatic elastase, and human 
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neutrophil elastase. Extracts from infective L3 A. ceylanicum only demonstrate inhibitory 
activity against human neutrophil elastase. This evidence suggests that AceKI-1 is a 
stage specific inhibitor expressed in adult A. ceylanicum and not the infective L3 stage. 
The conserved inhibition of human neutrophil elastase implies the possibility of a second 
protease inhibitor. In postulating the in vivo function of AceKI-1, we would expect an 
inhibitor of trypsin, chymotrypsin, and pancreatic elastase to be more useful in the adult 
stage parasite living in the hydrolytic environment of the intestine. We therefore more 
confidently predict that AceKI-1 has a biologic role in hookworm survival and that such a 
virulence factor may serve as a target for chemotherapeutic or vaccine development. 
As discussed earlier, no human vaccine exists for hookworm. Current hookworm 
control relies on anthelminthic therapy. With growing concern of drug resistance and 
prolonged exposure to these potentially toxic chemicals, the search for an alternative 
therapy, such as a vaccine, continues. Parasites have unique strategies that make vaccine 
development difficult. Hookworms are able to undergo antigenic changes during 
development, shed antibody bound surface coats to prevent host recognition, and secrete 
immunosuppressive molecules (96). These factors may explain why, although 
hookworms induce a host immune response, this response does not appear to protect 
against subsequent exposures and development of infection and disease (97). In 
identifying a vaccine target, it is important to remember the relationship between 
hookworm infection and hookworm disease. Unlike bacteria and viruses, where 
eradicating the organism is required for preventing disease, the goal for hookworm 
vaccine development may be different. Eliminating hookworms may not be necessary to 
alleviate hookworm anemia; interfering with the parasite’s virulence factors and 
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hindering blood loss might be sufficient (98). We must therefore identify what makes a 
virulence factor a suitable vaccine target. 
Many studies have used natural hookworm antigens in an attempt to induce 
immunity to hookworms. For example, by administering infective A. caninum larvae in 
numerous small doses, laboratory dogs were protected from challenge with large numbers 
of larvae (99). Regardless of their potentially protective benefit, however, it is not 
practical to immunize humans with living hookworm larvae, and additionally, human 
exposed to repeated hookworm infections have not developed sterile immunity. Many 
hookworm antigens, however, might serve as targets for inducing protective immunity 
including somatic antigens and excretory and secretory proteins. Early immunization 
trials with hookworm extracts were not successful, possibly due to the low concentration 
of potentially protective antigens and the presence of immunosuppressants in the extracts 
(96). Another study showed that immunization with either excretory and secretory (ES) 
product antigens or somatic antigens from A. ceylanicum yielded high antibody titers, but 
ES products provided greater protection (100). Most recently, work in a mouse model 
has shown that vaccination with recombinant ASP-1, the most abundantly secreted 
protein following activation of A. caninum L3, can reduce lung migration in mice 
challenged with infective hookworm larvae (101,102) and pooled antibody from 
immunized mice can protect naive mice against hookworm challenge (103). Based on 
observations that protective immunity can be generated from hookworm secreted 
antigens (104), we hope to create a genetically engineered vaccine for A. ceylanicum 
from a secreted antigen such as AceKI-1. 
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We have identified AceKI-1 activity in adult hookworm ES products, but there 
does not appear to be a natural host immunologic recognition of rAceKI-1. Using our 
laboratory hamster model, following forty days of infection with A. ceylanicum, hamster 
sera does not recognize recombinant AceKI-1. Hidden antigens are concealed from the 
immune system and therefore do not induce a normal immune response, and we 
conclude, therefore, that AceKI-1 is a hidden antigen (105,106). Although natural and 
overt antigens are more commonly used in vaccine development, hidden antigens can 
also be utilized to induce protection. The host inherently recognizes natural antigens as 
foreign and generates a humoral antibody response against them. Since humans for 
unknown reasons are unable to induce a protective response to natural hookworm 
antigens, a hidden antigen would be an alternative target. In hookworm, for example, if 
an antibody is engineered to target a hidden antigen in the parasites intestine, then that 
antibody will encounter its target during blood feeding. Binding the targeted hidden 
antigen may interfere with its role in parasite survival as has been demonstrated in 
Haemonchus contortus (105). 
We believe that AceKI-1 is a virulence factor that aids hookworm survival within 
its mammalian host. We have identified a similar inhibitory activity in soluble protein 
extracts from other species of adult hookworms, including A. caninum, and Necator 
americanus. Such a broadly conserved inhibitory activity further suggests that AceKI-1 
may be an evolutionary requirement for hookworm survival. By isolating a new serine 
protease inhibitor from hookworm, we hope to better understand how this specific 
parasite virulence factor is involved in the pathogenesis of hookworm associated 
gastrointestinal blood loss. Because the clinically relevant sequelae of hookworm 
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infection depend upon parasite survival in the host environment, interfering with these 
protein virulence factors using chemotherapeutics or immunotherapy may represent a 
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